Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study
Glenda Gray(South African Medical Research Council), James G. Kublin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Niles Eaton(Infectious Disease Research Institute), Zoe Moodie(Fred Hutch Cancer Center), Mary Allen(National Institutes of Health), Koleka Mlisana(Centre for the AIDS Programme of Research in South Africa), Gavin Churchyard(Aurum Institute), Adrian Puren(National Institute for Communicable Diseases), Guy de Bruyn(University of Namur), Linda‐Gail Bekker(Desmond Tutu HIV Foundation), Nivashnee Naicker(Centre for the AIDS Programme of Research in South Africa), Barbara Metch(Fred Hutch Cancer Center), Lawrence Corey(Emory University Hospital), Mary H. Latka(Aurum Institute), Michael Robertson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Donald K. Carter(Fred Hutch Cancer Center), Surita Roux(Desmond Tutu HIV Foundation), Margaret J McElrath(Fred Hutch Cancer Center), Constance Ducar(Fred Hutch Cancer Center), Matsontso Mathebula(Sefako Makgatho Health Sciences University), Maphoshane Nchabeleng(Sefako Makgatho Health Sciences University)
Cited by 385
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa
|The Lancet|2004|1.3k
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
|New England Journal of Medicine|1990|1.3k